Abstract:Background and Aim: Glioma is one of the most prevalent and refractory brain cancers with a high recurrence rate. Current limitations of experimental in vitro models include their inability to remodel the heterogeneity of the parental tumors and their incapacity to effectively reflect antitumor effects and mechanisms observable in vivo. Organoid models, as a new technology developed in recent years, can preserve the histological characteristics, cellular diversity, and gene expression of parental tumors to the fullest extent, thereby delivering more reliable data. This study intends to construct a simple organoid model developed from glioma patient material. Materials and Methods: Glioma samples were taken intraoperatively and cultured in the organoid medium using a continuous horizontal shaker. Sample collection and scientific research were authorized and approved by the Ethics Committee of Kowloon Hospital, China (Approval No. KY-2021-007). Immunofluorescence was applied to identify CD31 and Sox2 protein expression in the organoid model. The differences between primary glioblastomas and transplanted organoid tumors were analyzed by hematoxylin and eosin (H and E) staining. Immunohistochemistry (IHC) and Western blot assay were used to analyze the Sox2, Ki67, and CD31 protein expression levels. Results: The success rate of establishing organoid models was 90.9% in the primary glioblastomas, 75.0% in the WHO Grade III gliomas, and 42.9% in the Grade I–II gliomas. Immunofluorescence demonstrated that in vitro cultured organoids expressed CD31 and Sox2. Similarly, IHC and Western blot assay showed that orthotopically transplanted organoid tumors could exhibit high expressions of Sox2, Ki67, and CD31. There were no significant differences regarding the pathological features of primary glioblastomas and glioma organoid model as judged by H and E staining. Conclusions: This study presents a simple in vitro organoid model established from glioma patient samples. The success rate of constructing an organoid model is correlated with the degree of glioma malignancy. The established organoid model displays original model properties and simplifies the development of new experimental platforms that can support preclinical glioma treatment studies.

Construction of the Model of Primary Cultured Human Glioma Cells

A new method to culturing the human craniopharyngioma cell line

Isolation,Culture and Identification and Biological Character Research of Brain Tumor Stem Cells in Glioblastoma Multiforme in Vitro

The improved primary cell culture method of craniopharyngioma

Establishment and Validation of Glioma Patient-Derived Organoid Models

[Isolation and Culture of Tumor Stem Cells from Human Brain Glioma Tissues].

Establishment of Primary Cultures of Craniopharyngioma Cells

The Comparison Genomics Analysis with Glioblastoma Multiforme (GBM) Cells under 3D and 2D Cell Culture Conditions

Engineering a High-Throughput 3-D In Vitro Glioblastoma Model

Establishment and Identification of Human Primary Lung Cancer Cell Culture in Vitro.

The Establishment of Craniopharyngioma Cell Line

[Establishment of a New Human Glioma Cell Line and Analysis of Its Biological Characteristics].

Culture in vitro and identification of human cervical carcinoma cells

A Fast and Efficient Approach to Obtaining High-Purity Glioma Stem Cell Culture

The generation of glioma organoids and the comparison of two culture methods

Study on Primary Culture and Subculture of Prostate Cancer Cells

Establishment and Characterization of Human Glioblastoma Cell Line (HUBT-n)

Culture methods for primary cervical carcinoma cells

Cell Culture and Characterization of Solid Adamantinomatous Craniopharyngioma

Behaviors of Glioblastoma Cells in in Vitro Microenvironments